Mibefradil alters intracellular calcium concentration by activation of phospholipase C and IP3 receptor function
Autor: | Rodrigo S. Lacruz, Talita Ferreira Aguiar, Erna Mitaishvili, Guilherme Henrique Souza Bomfim |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
chemistry.chemical_element Pharmacology Calcium Calcium in biology 03 medical and health sciences Transient receptor potential channel 0302 clinical medicine TRPM7 HEK293 cells medicine Receptor Ca2+ signaling Mibefradil Phospholipase C Chemistry Research Cav ALC cells 030104 developmental biology 030220 oncology & carcinogenesis PLC pathway Medicine LS8 cells Intracellular medicine.drug |
Zdroj: | Molecular Biomedicine, Vol 2, Iss 1, Pp 1-13 (2021) Molecular Biomedicine |
ISSN: | 2662-8651 |
Popis: | Mibefradil is a tetralol derivative originally developed as an antagonist of T-type voltage-gated calcium (Ca2+) channels to treat hypertension when used at nanomolar dosage. More recently, its therapeutic application in hypertension has declined and has been instead repurposed as a treatment of cancer cell proliferation and solid tumor growth. Beyond its function as a Cav blocker, the micromolar concentration of mibefradil can stimulate a rise in [Ca2+]cyt although the mechanism is poorly known. The chanzyme TRPM7 (transient receptor potential melastanin 7), the release of intracellular Ca2+ pools, and Ca2+ influx by ORAI channels have been associated with the increase in [Ca2+]cyt triggered by mibefradil. This study aims to investigate the cellular targets and pathways associated with mibefradil’s effect on [Ca2+]cyt. To address these questions, we monitored changes in [Ca2+]cyt in the specialized mouse epithelial cells (LS8 and ALC) and the widely used HEK-293 cells by stimulating these cells with mibefradil (0.1 μM to 100 μM). We show that mibefradil elicits an increase in [Ca2+]cyt at concentrations above 10 μM (IC50 around 50 μM) and a fast Ca2+ increase capacity at 100 μM. We found that inhibiting IP3 receptors, depleting the ER-Ca2+ stores, or blocking phospholipase C (PLC), significantly decreased the capacity of mibefradil to elevate [Ca2+]cyt. Moreover, the transient application of 100 μM mibefradil triggered Ca2+ influx by store-operated Ca2+ entry (SOCE) mediated by the ORAI channels. Our findings reveal that IP3R and PLC are potential new targets of mibefradil offering novel insights into the effects of this drug. |
Databáze: | OpenAIRE |
Externí odkaz: |